Should We Treat Stroke Percutaneously in TAVR?

Since its inception, transcatheter aortic valve replacement (TAVR) has improved greatly. However, there still are five big challenges to be solved: paravalvular leak, conduction disturbances, debilitating stroke, impaired kidney function, and major vascular complications and bleeding.

¿Debemos realizar tratamiento percutáneo de los strokes en el TAVI?

Most cases of stroke are periprocedural and ischemic. So far, they have not been well analyzed in terms of their severity and resulting level of impairment in abilities. We also do not know which is the best treatment for each particular case.

The analysis included a total of 387 patients with stroke. Of these, 349 received conservative treatment (CT) and 39 received neurointervention (NI).

Stroke events were classified according to the National Institutes of Health Stroke Scale (NIHSS). Mild stroke had a score 0-5, moderate stroke had a score 6-14, and severe stroke were all events with a score ≥15.

Mean patient age was 81 years old; 52% of patients were male, 35% had diabetes, 13% had undergone previous myocardial revascularization surgery, 17% had experienced a previous infarction, 33% had undergone previous coronary angioplasty, and 35% had atrial fibrillation. The Society of Thoracic Surgeons mortality score was 5.9%.

Read also: RIPCORD 2 Study: Routine Assessment Using Pressure Wires in Acute Coronary Syndrome

Out of the patients who underwent TAVR, 12% did so in their bicuspid aortic valve, and 1.6% were valve-in-valve.

General anesthesia was used in 35% of cases, and self-expandable valves in 61%.

Stroke occurred within the first day (0-2 days). 

The most frequent stroke severity was mild, in 146 patients (49.6%), followed by severe in 75 (25.6%) and moderate in 73 (24.8%). The middle cerebral artery was the most frequently affected artery.

Read also: Are FFR and IVUS Similar to Assess Intermediate Lesions?

The NIHSS score was higher in patients who received NI (4 vs. 14 p < 0.001), and this strategy was used more frequently in cases of moderate or severe stroke (109 in the TC group and 36 in the NI arm).

Overall mortality at 30 days was 23.1%, at 6 months was 35%, and at 1 year was 42.1%. Moderate and severe stroke had a mortality 1.3 and 4.99 times higher compared with mild stroke, respectively.

There was no difference in mortality according to the degree of stroke severity between the two strategies at follow-up.

Read also: Is TCA Useful for Severe Impairment of Left Ventricular Ejection Fraction?

A logistic regression analysis was conducted and it showed that, in cases of severe stroke, the NI strategy increased 2.9 times the chance of survival at 90 days.

Conclusion

Acute ischemic stroke after TAVR has a high morbimortality risk correlated with stroke severity. Findings from this analysis suggest that patients with moderate or severe stroke could potentially improve with time after the intervention. It also highlights the importance of collaboration between cardiologists and neurologists to improve the evolution of acute ischemic stroke after TAVR.

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: Management and Outcome of Acute Ischemic Stroke Complicating Transcatheter Aortic Valve Replacement. on Behalf of the ASTRO-TAVI Study Group.

Reference: Amos Levi, et al. J Am Coll Cardiol Intv 2022. Article in Press.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

1-Year Outcomes of US TAVR Registry with 5th Generation Balloon Expandable Valves

The use of transcatheter aortic valve replacement (TAVR) has extended to younger patients with lower risk severe aortic stenosis (AS) and therefore the improvement...

EuroSMR Registry: Edge-to-Edge Mitral Treatment with 5-Year Outcomes

Cardiomyopathies and left atrial enlargement can lead to secondary mitral regurgitation (SMR). This condition is associated with ventricular dysfunction, causing heart failure, hospitalization, and...

TricValve Transcatheter Bicaval Valve System for Severe Tricuspid Insufficiency: Events at One Year

TricValve is the first bicaval valve system to obtain CE-Mark approval. This device heterotopic device eliminates tricuspid insufficiency reflux into the venous system, reducing...

Long Term Results of the International Chimney Registry

The International Chimney Registry was an observational study aimed at assessing the use of chimney stenting during TAVR either to predict or treat coronary...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

1-Year Outcomes of US TAVR Registry with 5th Generation Balloon Expandable Valves

The use of transcatheter aortic valve replacement (TAVR) has extended to younger patients with lower risk severe aortic stenosis (AS) and therefore the improvement...

EuroSMR Registry: Edge-to-Edge Mitral Treatment with 5-Year Outcomes

Cardiomyopathies and left atrial enlargement can lead to secondary mitral regurgitation (SMR). This condition is associated with ventricular dysfunction, causing heart failure, hospitalization, and...

TricValve Transcatheter Bicaval Valve System for Severe Tricuspid Insufficiency: Events at One Year

TricValve is the first bicaval valve system to obtain CE-Mark approval. This device heterotopic device eliminates tricuspid insufficiency reflux into the venous system, reducing...